The company said, “Pulmonx (LUNG) expects revenue for the full year 2025 to be in the range of $96 million to $98 million, representing growth of 15% to 17% compared to 2024, or 16% to 18% on a constant currency basis, as our guidance assumes a negative impact from foreign exchange on reported revenue growth of approximately 100 basis points. The Company expects gross margin for the full year 2025 to be approximately 74%. Pulmonx expects total operating expenses for the full year 2025 to fall within the range of $133 million to $135 million, inclusive of approximately $22 million of non-cash stock-based compensation.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUNG:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue